drugset / Trial / NCT00043836

The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure

NCT00043836 ↗

Phase 2 Completed 20 enrolled Synvista Therapeutics, Inc
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the hypothesis that treatment with oral ALT-711 twice daily for 16 weeks will improve aortic distensibility, exercise tolerance, and quality of life in elderly patients with isolated diastolic heart failure (DHF), and that the improvements in exercise tolerance will correlate with the improvements in aortic distensibility.

Timeline

Start
2002-07
Primary completion
2003-02
Completion
2005-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject alagebrium Small molecule — —